[Federal Register Volume 83, Number 40 (Wednesday, February 28, 2018)]
[Notices]
[Page 8658]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04066]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense.

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense (DoD) is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

DATES: Open to the public Thursday, April 5, 2018 from 9:00 a.m. to 
12:00 p.m.

ADDRESSES: The address of the open meeting is the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, U.S. Navy, 703-
681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington 
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: http://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date changes to the meeting agenda can be found 
on the website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    The Panel will review and comment on recommendations made to the 
Director of the Defense Health Agency, by the Pharmacy and Therapeutics 
Committee, regarding the Uniform Formulary.
    Purpose of the Meeting: The Department of Defense is publishing 
this notice to announce a Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel).
    Agenda: Meeting Agenda: 1. Sign-In. 2. Welcome and Opening Remarks. 
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item). a. Diabetes Non-Insulin: Glucagon-Like Peptide 1 Receptor 
Agonists Subclass. b. Osteoporosis Drugs: Parathyroid Hormone (PTH) 
Analog Subclass. c. Anti-Inflammatory Immunomodulatory Ophthalmic 
Agents--Ophthalmic Immunomodulatory Agents Subclass. d. 
Corticosteroids-Immune Modulators--Adrenocorticotropic Hormones 
Subclass. 4. Newly Approved Drugs Review. 5. Pertinent Utilization 
Management Issues. 6. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel about its mission and/or the agenda to be 
addressed in this public meeting. Written statements should be 
submitted to the Panel's Designated Federal Officer (DFO). The DFO's 
contact information can be obtained previously in this announcement. 
Written comments or statements must be received by the committee DFO at 
least five (5) business days prior to the meeting so that they may be 
made available to the Panel for its consideration prior to the meeting. 
The DFO will review all submitted written statements and provide copies 
to all the committee members.

    Dated: February 23, 2018.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2018-04066 Filed 2-27-18; 8:45 am]
BILLING CODE 5001-06-P